• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A Fusion Receptor as a Safety Switch, Detection, and Purification Biomarker for Adoptive Transferred T Cells.融合受体作为一种安全开关、检测和纯化过继转移 T 细胞的生物标志物。
Mol Ther. 2017 Oct 4;25(10):2270-2279. doi: 10.1016/j.ymthe.2017.06.026. Epub 2017 Jul 3.
2
Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.新型抗CD19嵌合抗原受体的构建及转导T细胞的抗白血病功能研究
Oncotarget. 2016 Mar 1;7(9):10638-49. doi: 10.18632/oncotarget.7079.
3
CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.通过CD19特异性嵌合抗原受体提供的CD28共刺激增强了过继转移T细胞在体内的持久性和抗肿瘤功效。
Cancer Res. 2006 Nov 15;66(22):10995-1004. doi: 10.1158/0008-5472.CAN-06-0160.
4
Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer.选择性双特异性 T 细胞募集抗体和过继性 T 细胞转移的抗肿瘤活性。
J Natl Cancer Inst. 2014 Nov 24;107(1):364. doi: 10.1093/jnci/dju364. Print 2015 Jan.
5
Tumor ablation by gene-modified T cells in the absence of autoimmunity.基因修饰 T 细胞在不引起自身免疫的情况下消融肿瘤。
Cancer Res. 2010 Dec 1;70(23):9591-8. doi: 10.1158/0008-5472.CAN-10-2884. Epub 2010 Nov 23.
6
Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFNγ.CAR T 细胞疗法在大肿瘤中的疗效依赖于 IFNγ 对基质的靶向作用。
Cancer Res. 2014 Dec 1;74(23):6796-805. doi: 10.1158/0008-5472.CAN-14-0079. Epub 2014 Oct 8.
7
Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.靶向癌症干细胞抗原EpCAM的前列腺癌过继性T细胞疗法。
BMC Immunol. 2015 Jan 31;16(1):1. doi: 10.1186/s12865-014-0064-x.
8
Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses.来那度胺通过增强免疫突触来增强嵌合抗原受体T细胞针对表皮生长因子受体变异体III的功能。
Cancer Gene Ther. 2015 Oct;22(10):487-95. doi: 10.1038/cgt.2015.47. Epub 2015 Oct 9.
9
Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.程序性死亡蛋白1的阻断增强了经工程改造靶向NY-ESO-1的人T细胞在过继转移后控制肿瘤生长的能力。
Clin Cancer Res. 2016 Jan 15;22(2):436-47. doi: 10.1158/1078-0432.CCR-15-1070. Epub 2015 Aug 31.
10
CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells.巨细胞病毒pp65疫苗增强了过继转移的CD19定向巨细胞病毒特异性T细胞的抗肿瘤功效。
Clin Cancer Res. 2015 Jul 1;21(13):2993-3002. doi: 10.1158/1078-0432.CCR-14-2920. Epub 2015 Apr 2.

引用本文的文献

1
Advances in strategies to improve the immunotherapeutic efficacy of chimeric antigen receptor-T cell therapy for lymphoma.提高嵌合抗原受体T细胞疗法治疗淋巴瘤免疫治疗效果的策略进展
Cancer Biol Med. 2025 Apr 15;22(4):301-21. doi: 10.20892/j.issn.2095-3941.2024.0538.
2
Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility.调整 CAR:修饰嵌合抗原受体 (CAR) T 细胞活性以提高安全性、疗效和灵活性的最新进展。
J Transl Med. 2023 Mar 15;21(1):197. doi: 10.1186/s12967-023-04041-6.
3
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?多发性骨髓瘤中 CAR T 或 BiTE 治疗的患者选择:每位患者的哪种治疗方法?
J Hematol Oncol. 2022 Jun 7;15(1):78. doi: 10.1186/s13045-022-01296-2.
4
Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review.新兴的 CAR T 细胞调控方法:综述
Front Immunol. 2020 Feb 26;11:326. doi: 10.3389/fimmu.2020.00326. eCollection 2020.
5
An IL-4/21 Inverted Cytokine Receptor Improving CAR-T Cell Potency in Immunosuppressive Solid-Tumor Microenvironment.IL-4/21 反向细胞因子受体增强 CAR-T 细胞在免疫抑制性实体瘤微环境中的效力。
Front Immunol. 2019 Jul 19;10:1691. doi: 10.3389/fimmu.2019.01691. eCollection 2019.
6
Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma.程序性死亡受体1(PD-1)的破坏增强了嵌合抗原受体T细胞对肝细胞癌的抗肿瘤活性。
Front Pharmacol. 2018 Oct 1;9:1118. doi: 10.3389/fphar.2018.01118. eCollection 2018.

本文引用的文献

1
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.复发或难治性霍奇金淋巴瘤患者使用维布妥昔单抗的5年生存率和疗效持久性结果
Blood. 2016 Sep 22;128(12):1562-6. doi: 10.1182/blood-2016-02-699850. Epub 2016 Jul 18.
2
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.急性淋巴细胞白血病嵌合抗原受体T细胞治疗后细胞因子释放综合征预测生物标志物的鉴定
Cancer Discov. 2016 Jun;6(6):664-79. doi: 10.1158/2159-8290.CD-16-0040. Epub 2016 Apr 13.
3
CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis.西妥昔单抗治疗的头颈癌患者中CTLA-4⁺调节性T细胞增加,抑制自然杀伤细胞的细胞毒性并与预后不良相关。
Cancer Res. 2015 Jun 1;75(11):2200-10. doi: 10.1158/0008-5472.CAN-14-2788. Epub 2015 Apr 1.
4
Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.靶向磷脂酰聚糖蛋白 3 的 T 细胞的开发用于治疗肝细胞癌。
Clin Cancer Res. 2014 Dec 15;20(24):6418-28. doi: 10.1158/1078-0432.CCR-14-1170. Epub 2014 Oct 15.
5
A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy.一种高度紧凑的基于表位的标记/自杀基因,用于更简单、更安全的 T 细胞治疗。
Blood. 2014 Aug 21;124(8):1277-87. doi: 10.1182/blood-2014-01-545020. Epub 2014 Jun 26.
6
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.19-28z嵌合抗原受体T细胞疗法治疗B细胞急性淋巴细胞白血病的疗效及毒性管理
Sci Transl Med. 2014 Feb 19;6(224):224ra25. doi: 10.1126/scitranslmed.3008226.
7
Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective.西妥昔单抗引起的皮肤疹:预防性和反应性皮肤治疗同样有效。
J Cancer Res Clin Oncol. 2013 Oct;139(10):1667-72. doi: 10.1007/s00432-013-1483-4. Epub 2013 Aug 7.
8
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.嵌合抗原受体修饰的 T 细胞治疗急性淋巴细胞白血病。
N Engl J Med. 2013 Apr 18;368(16):1509-1518. doi: 10.1056/NEJMoa1215134. Epub 2013 Mar 25.
9
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.CD19 靶向 T 细胞可迅速诱导化疗耐药的成人急性淋巴细胞白血病患者达到分子缓解。
Sci Transl Med. 2013 Mar 20;5(177):177ra38. doi: 10.1126/scitranslmed.3005930.
10
Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy.针对 EGFR 构象暴露的肿瘤特异性表位进行靶向治疗作为一种癌症治疗策略。
Cancer Res. 2012 Jun 15;72(12):2924-30. doi: 10.1158/0008-5472.CAN-11-3898. Epub 2012 Jun 1.

融合受体作为一种安全开关、检测和纯化过继转移 T 细胞的生物标志物。

A Fusion Receptor as a Safety Switch, Detection, and Purification Biomarker for Adoptive Transferred T Cells.

机构信息

State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200032, China.

CARsgen Therapeutics, Shanghai 200032, China.

出版信息

Mol Ther. 2017 Oct 4;25(10):2270-2279. doi: 10.1016/j.ymthe.2017.06.026. Epub 2017 Jul 3.

DOI:10.1016/j.ymthe.2017.06.026
PMID:28757080
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5628797/
Abstract

The incorporation of an endogenous safety switch represents a rational strategy for the control of toxicities following the administration of adoptive T cell therapies. An ideal safety switch should be capable of depleting the transferred T cells with minimal injury to normal tissues. We generated a fusion receptor by engineering a cryptic 806 epitope of human epidermal growth factor receptor (EGFR) into the N terminus of the full-length human folate receptor 1 (FOLR1), designated as FR806. The expression of FR806 allows transduced T cells to be targeted with CH12, a monoclonal antibody recognizing the 806 epitope, but not wild-type EGFR in healthy tissues. FR806, therefore, constitutes a specific cell-surface marker for the elimination of transduced T cells. We demonstrate that the antibody-drug conjugate (ADC) CH12-MMAF is efficiently internalized by FR806-expressing T cells and has the potential to eliminate them. Transfected T cells could, furthermore, be efficiently detected and purified using CH12 antibodies. In immuno-compromised mice, CH12-MMAF eliminated the majority of transferred T cells expressing FR806 and anti-CD19 chimeric antigen receptor (CAR). The selectivity for the 806 epitope and internalization capacity of FOLR1 makes FR806 an efficient safety switch, which may additionally be used as a detection and purification biomarker for human T cell immunotherapies.

摘要

内源性安全开关的整合代表了一种控制过继性 T 细胞疗法后毒性的合理策略。理想的安全开关应该能够在最小化对正常组织损伤的情况下耗尽转移的 T 细胞。我们通过将人类表皮生长因子受体 (EGFR) 的隐蔽 806 表位工程设计到全长人叶酸受体 1 (FOLR1) 的 N 端,生成了一种融合受体,命名为 FR806。FR806 的表达使转导的 T 细胞能够被靶向识别 806 表位的单克隆抗体 CH12 识别,但不能被健康组织中的野生型 EGFR 识别。因此,FR806 构成了用于消除转导 T 细胞的特异性细胞表面标记物。我们证明,抗体药物偶联物 (ADC) CH12-MMAF 被表达 FR806 的 T 细胞有效内化,并具有消除它们的潜力。此外,转染的 T 细胞可以使用 CH12 抗体高效地检测和纯化。在免疫功能低下的小鼠中,CH12-MMAF 消除了表达 FR806 和嵌合抗原受体 (CAR) 的大多数转移的 T 细胞。FOLR1 对 806 表位的选择性和内化能力使 FR806 成为一种有效的安全开关,它还可以用作人类 T 细胞免疫疗法的检测和纯化生物标志物。